Zolmitriptan shortage — AU supply status & alternatives

Zolmitriptan

ATC N02CC03

🇦🇺 AUST R 388593

In shortage · Australia

ZOLTRIP zolmitriptan

In declared shortage · 🇦🇺 Australia & also short in🇨🇦 CA🇩🇪 DE🇮🇹 IT🇧🇪 BE🇳🇱 NL

Critical shortage

Reading today’s signals…

🇦🇺 AUAEMPA$5.52DPMQ A$25.88details →

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

Rizatriptan

◷ Expected back

Product attributes reference data we hold

Active ingredient (INN)	Zolmitriptan
Brand names	ZOLTRIP zolmitriptan
ATC level 5	N02CC03
ATC level 4	N02CC
Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper
Controlled substance	No
Marketing-authorisation holders	ACCORD-UK LIMITED, GENUS PHARMACEUTICALS LIMITED, CRESCENT PHARMA LIMITED, GRUNENTHAL LIMITED +1 more
Registrations on file	12
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$5.52

AEMP

Dispensed (DPMQ)

A$25.88

incl. fees

Pack

zolmitriptan 2.5 mg tablet, 2

Source: PBSEffective July 2026 · AUD

Other markets

🇬🇧 GB

£3.14

Drug Tariff

🇺🇸 US

US$2.27

Acquisition

🇮🇹 IT

€13.59

Retail price

🇪🇸 ES

€16.08

Retail price

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

17 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Low concentration risk

Apitoria Pharma Private LTDMatrix Pharmacorp Private LTDHetero Drugs LTDSms Pharmaceuticals LTDNatco Pharma LTDTapi Nl BV+11 more

Manufacturing countries: India, Spain, Taiwan · Source: FDA List of Drug Master Files

Shortage status by regulator official notices

🇦🇺

Australia

TGA · 2h ago

Critical

🇨🇦

Canada

HC · 2h ago

Medium

🇧🇪

FAMHP · 3h ago

Medium

🇳🇱

Netherlands

CBG-MEB · 7h ago

Medium

🇮🇹

Italy

AIFA · 1d ago

Medium

🇩🇪

Germany

BfArM · 1d ago

Medium

🇳🇴

Norway

NOMA · 3d ago

Resolved

🇪🇸

Spain

AEMPS · 1mo ago

Resolved

Verified timeline regulator events

🇳🇱 30 June 2026

medium reported

🇮🇹 30 June 2026

Shortage resolved

🇳🇱 19 June 2026

medium reported

🇳🇱 17 June 2026

medium reported

🇳🇱 8 June 2026

medium reported

🇧🇪 2 June 2026

medium reported

Sources official regulators

🇨🇦

verified 2h ago

verify ↗

🇦🇺

TGA

verified 2h ago

verify ↗

🇧🇪

FAMHP

verified 3h ago

verify ↗

🇳🇱

CBG-MEB

verified 7h ago

verify ↗

🇮🇹

AIFA

verified 8h ago

verify ↗

🇩🇪

BfArM

verified 1d ago

verify ↗

🇳🇴

NOMA

verified 3d ago

verify ↗

🇪🇸

AEMPS

verified 1mo ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders12 registrations · 5 MA holders

Product	Strength	Form	Market	MA holder	Status
ZOLTRIP ACUTE MIGRAINE RELIEF zolmitriptan	2.5 mg	—	🇦🇺 AU	—	Active
Chemists' Own Acute Migraine Relief Zolmitriptan	2.5 mg	—	🇦🇺 AU	—	Active
Apohealth Acute Migraine Relief Zolmitriptan	2.5 mg	—	🇦🇺 AU	—	Active
ZOLMITRIPTAN 2.5 MG FILM-COATED TABLETS	2.5 MG	tablet	🇬🇧 GB	ACCORD-UK LIMITED	Active
ZOLMITRIPTAN 5MG FILM-COATED TABLETS	5MG	tablet	🇬🇧 GB	ACCORD-UK LIMITED	Active
ZOLMITRIPTAN 2.5MG ORODISPERSIBLE TABLETS	2.5MG	tablet	🇬🇧 GB	ACCORD-UK LIMITED	Active
ZOLMITRIPTAN 5MG ORODISPERSIBLE TABLETS	5MG	tablet	🇬🇧 GB	ACCORD-UK LIMITED	Active
ZOLMITRIPTAN 5 MG ORODISPERSIBLE TABLETS	5 MG	tablet	🇬🇧 GB	GENUS PHARMACEUTICALS LIMITED	Active
ZOLMITRIPTAN 2.5 MG ORODISPERSIBLE TABLETS	2.5 MG	tablet	🇬🇧 GB	GENUS PHARMACEUTICALS LIMITED	Active
ZOLMITRIPTAN 2.5MG FILM-COATED TABLETS	2.5MG	tablet	🇬🇧 GB	CRESCENT PHARMA LIMITED	Active
Zolmitriptan Grunenthal	5 MG	spray	🇬🇧 GB	GRUNENTHAL LIMITED	Active
ZOLMITRIPTAN 5 MG FILM-COATED TABLETS	5 MG	tablet	🇬🇧 GB	GLENMARK PHARMACEUTICALS EUROPE LIMITED	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.